State of the art in anti-cancer mAbs

Autores
Chiavenna, Sebastián Matias; Jaworski, Juan Pablo; Vendrell, Alejandrina
Año de publicación
2017
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Following Milstein’s discovery, the monoclonal antibodies (mAbs) became a basic tool for biomedical science. In cancer field, since the first mAb was approved by the FDA a great improvement took place making of them a therapeutic option for many cancer types in the current clinical practice. Today, mAbs are being developed to target different molecules with different mechanisms of action and its target potential is unlimited. However, this huge and fast growing new field needs to be organized to better understand the treatment options we have to confront different cancer diseases. Current cancer targeted immunotherapies aim to achieve different goals like the regulation of osteoclast function, the delivery of cytotoxic drugs into tumor cells and the blockade of oncogenic pathways, neo-angiogenesis and immune checkpoints. Here, we reviewed the most relevant therapeutic mAbs for solid tumors available in current clinical practice.
Fil: Chiavenna, Sebastián Matias. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Ferrer Internacional. Ferrer Advanced Biotherapeutics; España
Fil: Jaworski, Juan Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Instituto Nacional de Tecnología Agropecuaria. Centro de Investigación en Ciencias Veterinarias y Agronómicas. Instituto de Virología; Argentina
Fil: Vendrell, Alejandrina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
Materia
CANCER
CTLA-4
EGFR
HER2
IMMUNOTHERAPY
MONOCLONAL ANTIBODY
PD-1/PD-L1
RANK/RANKL
SOLID TUMORS
VEGF/VEGFR
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/72885
Acceder
id CONICETDig_88b3db93968294e4ac0df969b8d2d622
oai_identifier_str oai:ri.conicet.gov.ar:11336/72885
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling State of the art in anti-cancer mAbsChiavenna, Sebastián MatiasJaworski, Juan PabloVendrell, AlejandrinaCANCERCTLA-4EGFRHER2IMMUNOTHERAPYMONOCLONAL ANTIBODYPD-1/PD-L1RANK/RANKLSOLID TUMORSVEGF/VEGFRhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Following Milstein’s discovery, the monoclonal antibodies (mAbs) became a basic tool for biomedical science. In cancer field, since the first mAb was approved by the FDA a great improvement took place making of them a therapeutic option for many cancer types in the current clinical practice. Today, mAbs are being developed to target different molecules with different mechanisms of action and its target potential is unlimited. However, this huge and fast growing new field needs to be organized to better understand the treatment options we have to confront different cancer diseases. Current cancer targeted immunotherapies aim to achieve different goals like the regulation of osteoclast function, the delivery of cytotoxic drugs into tumor cells and the blockade of oncogenic pathways, neo-angiogenesis and immune checkpoints. Here, we reviewed the most relevant therapeutic mAbs for solid tumors available in current clinical practice.Fil: Chiavenna, Sebastián Matias. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Ferrer Internacional. Ferrer Advanced Biotherapeutics; EspañaFil: Jaworski, Juan Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Instituto Nacional de Tecnología Agropecuaria. Centro de Investigación en Ciencias Veterinarias y Agronómicas. Instituto de Virología; ArgentinaFil: Vendrell, Alejandrina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; ArgentinaBioMed Central2017-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/72885Chiavenna, Sebastián Matias; Jaworski, Juan Pablo; Vendrell, Alejandrina; State of the art in anti-cancer mAbs; BioMed Central; Journal Of Biomedical Science; 24; 1; 2-20171021-7770CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1186/s12929-016-0311-yinfo:eu-repo/semantics/altIdentifier/url/https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-016-0311-yinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-10T13:05:41Zoai:ri.conicet.gov.ar:11336/72885instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-10 13:05:41.51CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv State of the art in anti-cancer mAbs
title State of the art in anti-cancer mAbs
spellingShingle State of the art in anti-cancer mAbs
Chiavenna, Sebastián Matias
CANCER
CTLA-4
EGFR
HER2
IMMUNOTHERAPY
MONOCLONAL ANTIBODY
PD-1/PD-L1
RANK/RANKL
SOLID TUMORS
VEGF/VEGFR
title_short State of the art in anti-cancer mAbs
title_full State of the art in anti-cancer mAbs
title_fullStr State of the art in anti-cancer mAbs
title_full_unstemmed State of the art in anti-cancer mAbs
title_sort State of the art in anti-cancer mAbs
dc.creator.none.fl_str_mv Chiavenna, Sebastián Matias
Jaworski, Juan Pablo
Vendrell, Alejandrina
author Chiavenna, Sebastián Matias
author_facet Chiavenna, Sebastián Matias
Jaworski, Juan Pablo
Vendrell, Alejandrina
author_role author
author2 Jaworski, Juan Pablo
Vendrell, Alejandrina
author2_role author
author
dc.subject.none.fl_str_mv CANCER
CTLA-4
EGFR
HER2
IMMUNOTHERAPY
MONOCLONAL ANTIBODY
PD-1/PD-L1
RANK/RANKL
SOLID TUMORS
VEGF/VEGFR
topic CANCER
CTLA-4
EGFR
HER2
IMMUNOTHERAPY
MONOCLONAL ANTIBODY
PD-1/PD-L1
RANK/RANKL
SOLID TUMORS
VEGF/VEGFR
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Following Milstein’s discovery, the monoclonal antibodies (mAbs) became a basic tool for biomedical science. In cancer field, since the first mAb was approved by the FDA a great improvement took place making of them a therapeutic option for many cancer types in the current clinical practice. Today, mAbs are being developed to target different molecules with different mechanisms of action and its target potential is unlimited. However, this huge and fast growing new field needs to be organized to better understand the treatment options we have to confront different cancer diseases. Current cancer targeted immunotherapies aim to achieve different goals like the regulation of osteoclast function, the delivery of cytotoxic drugs into tumor cells and the blockade of oncogenic pathways, neo-angiogenesis and immune checkpoints. Here, we reviewed the most relevant therapeutic mAbs for solid tumors available in current clinical practice.
Fil: Chiavenna, Sebastián Matias. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Ferrer Internacional. Ferrer Advanced Biotherapeutics; España
Fil: Jaworski, Juan Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Instituto Nacional de Tecnología Agropecuaria. Centro de Investigación en Ciencias Veterinarias y Agronómicas. Instituto de Virología; Argentina
Fil: Vendrell, Alejandrina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
description Following Milstein’s discovery, the monoclonal antibodies (mAbs) became a basic tool for biomedical science. In cancer field, since the first mAb was approved by the FDA a great improvement took place making of them a therapeutic option for many cancer types in the current clinical practice. Today, mAbs are being developed to target different molecules with different mechanisms of action and its target potential is unlimited. However, this huge and fast growing new field needs to be organized to better understand the treatment options we have to confront different cancer diseases. Current cancer targeted immunotherapies aim to achieve different goals like the regulation of osteoclast function, the delivery of cytotoxic drugs into tumor cells and the blockade of oncogenic pathways, neo-angiogenesis and immune checkpoints. Here, we reviewed the most relevant therapeutic mAbs for solid tumors available in current clinical practice.
publishDate 2017
dc.date.none.fl_str_mv 2017-02
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/72885
Chiavenna, Sebastián Matias; Jaworski, Juan Pablo; Vendrell, Alejandrina; State of the art in anti-cancer mAbs; BioMed Central; Journal Of Biomedical Science; 24; 1; 2-2017
1021-7770
CONICET Digital
CONICET
url http://hdl.handle.net/11336/72885
identifier_str_mv Chiavenna, Sebastián Matias; Jaworski, Juan Pablo; Vendrell, Alejandrina; State of the art in anti-cancer mAbs; BioMed Central; Journal Of Biomedical Science; 24; 1; 2-2017
1021-7770
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1186/s12929-016-0311-y
info:eu-repo/semantics/altIdentifier/url/https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-016-0311-y
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv BioMed Central
publisher.none.fl_str_mv BioMed Central
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842980216858738688
score 12.993085

Publicaciones similares